Literature DB >> 16397859

A population model of prostate cancer incidence.

A Tsodikov1, A Szabo, J Wegelin.   

Abstract

Introduction of screening for prostate cancer using the prostate-specific antigen (PSA) marker of the disease led to remarkable dynamics of the incidence of the disease observed in the last two decades. A statistical model is used to provide a link between dissemination of PSA and the observed transient population responses. The model is used to estimate lead time, overdiagnosis and other relevant characteristics of prostate cancer screening. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16397859     DOI： 10.1002/sim.2257

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


  29 in total

1.  Calibrating disease progression models using population data: a critical precursor to policy development in cancer control.

Authors:  Roman Gulati; Lurdes Inoue; Jeffrey Katcher; William Hazelton; Ruth Etzioni
Journal:  Biostatistics       Date:  2010-06-07       Impact factor: 5.899

2.  Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies.

Authors:  Roman Gulati; Eric J Feuer; Ruth Etzioni
Journal:  Am J Epidemiol       Date:  2016-06-29       Impact factor: 4.897

3.  Optimal healthcare decision making under multiple mathematical models: application in prostate cancer screening.

Authors:  Dimitris Bertsimas; John Silberholz; Thomas Trikalinos
Journal:  Health Care Manag Sci       Date:  2016-09-17

Review 4.  Calibration methods used in cancer simulation models and suggested reporting guidelines.

Authors:  Natasha K Stout; Amy B Knudsen; Chung Yin Kong; Pamela M McMahon; G Scott Gazelle
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

5.  Focal therapy for localized prostate cancer -choosing the middle ground.

Authors:  Uri Lindner; John Trachtenberg
Journal:  Can Urol Assoc J       Date:  2009-08       Impact factor: 1.862

6.  Expected population impacts of discontinued prostate-specific antigen screening.

Authors:  Roman Gulati; Alex Tsodikov; Ruth Etzioni; Rachel A Hunter-Merrill; John L Gore; Angela B Mariotto; Matthew R Cooperberg
Journal:  Cancer       Date:  2014-07-25       Impact factor: 6.860

7.  Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.

Authors:  Roman Gulati; John L Gore; Ruth Etzioni
Journal:  Ann Intern Med       Date:  2013-02-05       Impact factor: 25.391

Review 8.  Prostate cancer in young men: an important clinical entity.

Authors:  Claudia A Salinas; Alex Tsodikov; Miriam Ishak-Howard; Kathleen A Cooney
Journal:  Nat Rev Urol       Date:  2014-05-13       Impact factor: 14.432

9.  Is prostate cancer different in black men? Answers from 3 natural history models.

Authors:  Alex Tsodikov; Roman Gulati; Tiago M de Carvalho; Eveline A M Heijnsdijk; Rachel A Hunter-Merrill; Angela B Mariotto; Harry J de Koning; Ruth Etzioni
Journal:  Cancer       Date:  2017-04-24       Impact factor: 6.860

10.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

Authors:  Gerrit Draisma; Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Elisabeth Wever; Roman Gulati; Eric Feuer; Harry de Koning
Journal:  J Natl Cancer Inst       Date:  2009-03-10       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.